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ABSTRACT
MicroRNAs fine-tune the activity of hundreds of
protein-coding genes. The identification of
tissue-specific microRNAs and their promoters has
been constrained by the limited sensitivity of prior
microRNA quantification methods. Here, we deter-
mine the entire microRNAome of three endoderm-
derived tissues, liver, jejunum and pancreas, using
ultra-high throughput sequencing. Although many
microRNA genes are expressed at comparable
levels, 162 microRNAs exhibited striking tissue-
specificity. After mapping the putative promoters
for these microRNA genes using H3K4me3 histone
occupancy, we analyzed the regulatory modules of
63 microRNAs differentially expressed between liver
and jejunum or pancreas. We determined that
the same transcriptional regulatory mechanisms
govern tissue-specific gene expression of both
mRNA and microRNA encoding genes in mammals.
INTRODUCTION
MicroRNAs are short non-coding RNAs of 21–23nt that
are present in multiple organisms and that are often evo-
lutionarily conserved (1). MicroRNAs function by sup-
pressing the expression of protein coding genes, with
each microRNA targeting dozens or even hundreds of
mRNAs. In mammals, microRNA function on a global
level has been studied through mutational analysis
of Dicer, an obligate enzyme in the processing of
microRNA precursors. Thus, it was shown that
microRNAs are required for ES self-renewal as well as
development and function of tissues including liver (2,3),
intestine (4) and heart (5).
There are more than 1000 microRNAs encoded in the
mammalian genome, and these are derived from a
complex series of processing steps. The primary transcript,
or pri-microRNA, synthesized by RNA polymerase II or
III is very labile, and quickly converted to  70nt precur-
sors, termed pre-microRNA (6). These pre-microRNAs
exist as hairpins and are further processed through a
series of endonuclease digestion steps to the ﬁnal and func-
tional microRNAs, which are loaded onto the so-called
RNA inducing silencing complex (RISC) to exert their
regulatory functions. Because of their very short
sequence, quantiﬁcation of microRNAs by array-based
technologies has its limitations, as the hybridization con-
ditions used cannot be optimized for all microRNA
probes simultaneously. Previous tissue surveys used
cloning and sequencing to determine the microRNA
abundance in multiple tissues at low sequencing depth.
While these assays could not capture the entire
microRNAome, they nevertheless established that
microRNAs are expressed in a tissue-speciﬁc manner (7).
Recent studies have demonstrated that transcription
factors can regulate microRNA expression; however,
binding sites have been conﬁrmed experimentally for
only a small number of microRNA promoters, and little
is known about the mechanisms that inﬂuence
tissue-speciﬁc expression of microRNAs (8–10). In order
to elucidate the regulatory networks that govern
tissue-speciﬁc expression of microRNA genes, we
determined their complete expression proﬁle by ultra-high
throughput sequencing in three endoderm-derived tissues.
The greatly expanded number of differentially expressed
microRNAs identiﬁed through this method provided suf-
ﬁcient sequence depth to determine the cis-regulatory
modules that control the differentially expressed
microRNA genes. Moreover, the results of our analysis
established that microRNA genes are governed by the
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protein-coding genes.
MATERIALS AND METHODS
Processing microRNA reads
Male CD-1 mice aged 8–12-week-old (Charles River
Laboratories) underwent liver harvest between 8 AM
and 12 PM. Small intestinal mucosa was isolated via
mucosal scraping. Pancreata were harvested from the
same mice and snap frozen. Chromatin was later
prepared from a portion of the frozen tissue as described
earlier (11) except that protease inhibitors were also
included in the PBS and cell lysis buffers. H3K4Me3
ChIP was performed as described earlier (12). Total
and small RNAs were extracted using the mirVana
microRNA Isolation kit (Cat. # AM1561, Ambion,
Austin, TX, USA). Small RNAs libraries were generated
using the DGE-small RNA Sample prep kit (Cat. #
FC-102-1009; Illumina, San Diego, CA, USA). Illumina
sequencing libraries were prepared using the ‘long’
Illumina protocol according to the manufacturer’s direc-
tions. Puriﬁed PCR product was loaded on an Agilent
Technologies 2100 Bioanalyzer to conﬁrm sample
quantity and integrity. Reads from six liver, ﬁve
small intestinal mucosa, and two pancreas samples were
sequenced on an Illumina GA-II following manufactur-
er’s instructions. The 30-adapter was trimmed from the
end of each read and the frequencies of the resulting
oligos were tabulated for each lane and in total. The
oligos were aligned to precursor hairpins (mirBase 14),
RefSeq sequences, and the mouse genome (NCBI Build
36; mm8) using ELAND and allowing up to two
mismatches. Alignments of reads in the length range
19–25bp were assigned to the mature microRNA that
they overlapped. When mature forms shared an oligo
in this length range, they were merged into an ad hoc
family for reporting read counts and for differential ex-
pression calculations. All high-throughput sequencing
data are accessible from the NCBI Short Read Archive
under accession number SRA023764.
Identifying differentially-expressed microRNAs
To identify differentially-expressed microRNAs we used
read counts in reads per million (RPM) from six replicates
from liver, ﬁve from small intestine, and two from
pancreas. The RPM values were quantile normalized in
R using the normalizeBetweenArrays function of the
limma package. These values were then analyzed using
SAMR, and microRNAs with an FDR  10%, a
minimum of 1.5-fold change, and at least 100 RPM
average expression (in the appropriate tissue) were
selected as differentially expressed.
ChIP for histone modiﬁcations
Immunoprecipitations were performed as described earlier
(11), except that 4mg of chromatin and 4mg of antibodies
were used for each reaction. Chromatin was immunopre-
cipitated with antibodies for H3K4me3 (Millipore, Cat#
CS200580). Immunoprecipitation was conﬁrmed by
calculating enrichment of control liver, jejunal mucosa
and pancreas expressed genes using control intergenic
regions, by comparing input DNA to ChIP DNA. The
immunoprecipitated DNA was prepared for sequencing
as per Illumina’s instructions (http://www.illumina.com)
and previously described (13). High-throughput
sequencing was performed on an Illumina GA-II follow-
ing manufacturer’s instructions. The 36-bp reads were
aligned to the mouse genome (NCBI Build 36; mm8)
using ELAND and allowing up to two mismatches.
Reads with a unique best alignment were included in
further processing (liver H3K4me3 ChIP: 7720909,
input: 12056786; small intestine H3K4me3 ChIP:
8492668, input: 11961006, pancreas H3K4me3 ChIP:
20176620).
Identifying regions of signiﬁcant H3K4me3 modiﬁcation
We used GLITR (13) to identify regions of signiﬁcant
enrichment of H3K4me3 as compared to input using a
1% FDR. Adjacent GLITR regions in each tissue were
merged if they were within 1500bp. The merged regions
were considered to be candidate TSSs. We created an
atlas of all H3K4me3 regions by merging overlapping
regions from all three endodermal tissues. To quantify
the strength of modiﬁcation in each tissue, we
computed the length-normalized rate of tissue-speciﬁc
reads (reads per kilo basepair), then applied quantile nor-
malization to correct for differences in total read count
and ChIP efﬁciency. The closest H3K4me3 peak with a
normalized intensity of at least 25 reads and within
200000-bp upstream of a pre-miRNA was considered
its most likely transcriptional start site. Only
microRNAs with a normalized intensity of at least 32
RPM were considered.
Identifying enriched predicted transcription
factor binding sites
We selected putative TSS for liver-expressed microRNA
genes. We extracted sequence covering ±2kb from the
middle of the putative TSS and masked out
poorly-conserved regions by removing areas with a
phastCons score <0.15 in the UCSC 17-way vertebrate
conservation track. The phastCons score ranges between
0 (not conserved) and 1 (well conserved). Regions with
similar dimensions anchored at the TSS of protein
coding genes were selected as a background set. The back-
ground set was chosen so that it had the same joint dis-
tribution of conserved sequence and base composition as
the microRNA promoters. Receiver-operating character-
istic (ROC) curves were computed for each vertebrate
PWM in TRANSFAC (v2009.2) by varying the scoring
threshold. P-values were computed for each score thresh-
old that yielded a hit in an additional microRNA TSS
using a chi-squared distribution for each threshold that
yielded hits >5 microRNA or background TSSs. The
best chi-squared P-value was tracked for each PWM.
The best P-value was corrected for multiple testing using
a Bonferroni factor equal to the number of tests, which we
took to be the number of positive regions microRNA TSS
Nucleic AcidsResearch, 2011, Vol.39,No. 2 455regions (between 25 and 32 depending on the compari-
son), multiplied by the number of PWMs (644 vertebrate
PWMs). This is a conservative correction as many of the
TRANSFAC PWMs are similar and therefore do not con-
stitute independent trials which the Bonferroni correction
assumes. We also tested HNF4a sites using the SVM
(support vector machine) prediction method developed
by Sladek and colleagues (14). We submitted all sequences
to the website and tabulated the best score for each
masked sequence. The chi-squared P-value was 0.00013
which we corrected to 0.00013 * 39=0.0052.
Associating Foxa2-binding sites with TSS regions
We assumed that a Foxa2-binding event is likely to
regulate the gene or microRNA associated with the
closest H3K4me3 region to the Foxa2 site. However, in
cases where a binding site was located in the common
promoter of divergently transcribed genes, in an
array with overlapping genes, or in an intergenic region
adjacent to multiple genes, identifying the target gene was
less straightforward. We assigned experimentally-deﬁned
Foxa2-binding events to the gene with a H3K4me3 region
that was closest to the Foxa2 site, as well as any additional
genes with a H3K4me3 region that was no >50% further
than the closest region.
Visualizing genomic data
The positions of expressed miRNAs, genes, H3K4me3
regions and proﬁles, miRNA-TSS associations from this
and previous work were visualized using the TessLA
system which consists of a genome browser and a data
analysis tool kit (unpublished data).
RESULTS AND DISCUSSION
The microRNAome of liver, jejunum and pancreas
We isolated small RNA fractions from six livers, six
samples of small intestinal mucosa (from the jejunum)
and two pancreata, converted them into libraries, and
obtained 26574536, 55 885 851 and 38613301 sequence
reads for liver, jejunal mucosa and pancreas, respectively.
The resulting sequence reads were aligned to known
microRNA precursor genes, obtained from miRBase v14
(15), in order to assess the abundance of each mature
microRNA. Next, we veriﬁed that our sequence reads rep-
resented microRNAs and not degraded mRNAs by
aligning them to the RefSeq database as well. As shown
in Supplementary Figure S1, <10% of the reads in the
microRNA size range (21–23nt) aligned to mRNAs,
while >80% matched to precursor microRNAs, indicating
that our small RNA preparation was highly enriched for
true microRNAs. In total, we generated 19 754 019, 45 949
823 and 13 487 288 trimmed reads in the range of 19–25nt
that aligned to precursor microRNAs for liver, jejunum
and pancreas, respectively. Using these reads, we found
evidence for expression of 769 of the 1094 (69.9%)
known or predicted mature microRNAs, corresponding
to 459 of 547 (83.9%) pre-microRNAs. (Supplementary
Table S1). We conﬁrmed high-level expression of
previously known abundant microRNAs in the respective
tissue, such as mir-122 and mir-192 in the liver, miR-215
and miR-192 in the intestine, and miR-375 and miR-152
in the pancreas (Supplementary Table S1) (16–20). The
let-7 family was highly expressed in all tissues. The extra-
ordinary dynamic range (about six orders of magnitude)
of the technology used allowed us to detect and quantify
microRNAs present in a few copies per million as well as
those that contribute up to  44% of the total microRNA
pool, i.e. miR-122 in the liver. Because of technical limi-
tations of prior efforts, many of the microRNAs identiﬁed
here had been missed in previous studies (7,21).
Tissue-speciﬁc microRNA expression
Next, we determined the differential microRNA gene ex-
pression between the three tissues. To this end, we
employed computational tools established previously for
the analysis of microarray expression proﬁling (for details,
see ‘Materials and Methods’ section). After quantile nor-
malization, expression levels of the independent samples
for each tissue were compared. As shown in Figure 1,
most microRNA genes are expressed at similar levels
between any two tissues, suggesting that organs of
related developmental origin such as liver and intestinal
mucosa co-express many microRNA genes, just as they
co-express many protein-coding genes. However, 162
microRNA genes exhibited statistically signiﬁcant enrich-
ment in either liver (63), small intestine (65) or pancreas
(96), with differential expression of up to 120000-fold.
The top 30 microRNAs enriched in each organ versus
the other two are listed in Tables 1–3. Full lists are avail-
able in Supplementary Tables S2–S4; see also
Supplementary Figure S2.
Mapping transcriptional start sites of microRNAs
The analysis of cis-regulatory elements requires know-
ledge of the promoter used for the microRNA gene in
question in the liver, small intestine or pancreas. To this
end, we took advantage of the recent discovery that tran-
scriptional start sites in the mammalian genome are
marked by trimethylated histone H3 (H3K4me3), often
in a characteristic double peak pattern (22). We performed
ChIP-Seq experiments for H3K4me3 in liver, small intes-
tine and pancreas, identiﬁed areas of H3K4me3 enrich-
ment, and then mapped these putative transcriptional
start sites to expressed microRNAs by associating each
microRNA with the nearest upstream region of
H3K4me3 occupancy. To increase the chances that a
microRNA would have an H3K4me3-marked TSS, we
only processed microRNAs that had an expression level
of at least 32 RPM, and required that the H3K4me3 en-
richment levels reached at least 25 (see ‘Materials and
Methods’ section for details.) Of a total of 17505
H3K4me3 regions present in at least one organ, we
identiﬁed 106 as putative TSS for a total of 128
pre-miRNAs (Supplementary Table S5). About 80% of
the TSS were within 50kb of the miRNA
(Supplementary Figure S3). As found previously for the
analysis of microRNA promoters in embryonic stem cells,
between 73.3% (jejunum) and 77.6% (pancreas) (Table 4)
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start sites overlapped CpG islands, a DNA sequence
feature frequently associated with promoters. We
compared microRNA expression levels to the degree of
H3K4me3 occupancy at their promoters, but did not
observe any obvious correlation (data not shown).
Comparing our results with previous efforts that had
mapped transcriptional start sites in ES cells (23), we
found agreement at 59 of 106 (55.7%) of our H3K4me3
loci. Reasons for this discrepancy might include the
reliance on historic H3K4me3 mapping data in the
previous study, and the use of different transcriptional
start sites in liver and intestinal mucosa compared to em-
bryonic stem cells. We observe that the average concord-
ance rate within a given organ (64.5%) is higher than the
rate over all identiﬁed miRNA/TSS pairs, which is con-
sistent with the idea that the TSS concordant between ES
cells and a given organ or tissue correspond to ‘housekeep-
ing’ miRNAs which are used in most tissues. As we deter-
mine TSS in different endoderm-derived tissues,
we identify additional tissue-speciﬁc microRNA/TSS,
while still re-identifying the same housekeeping
microRNA/TSS, thus lowering the total concordance
rate. A few examples of this latter category are discussed
below. Figures 2 and 3 illustrate the advantage of identify-
ing tissue-speciﬁc microRNA transcriptional start sites
using H3K4me3 mapping in tissues that express the
microRNA in question, and also illustrate the regulatory
complexity of miRNAs. In Figure 4 we show strong local
promoters active in liver and small intestine where
miRNAs miR-192 and miR-194 are highly-expressed. In
pancreas, the expression of these miRNAs is about 10 
lower, though still strong, but the level of H3K4me3 has
been reduced to background levels. Marson and col-
leagues identiﬁed a promoter region further upstream in
the Atg2a gene, which is also at background levels in
pancreas (23). However, the CpG-containing promoter
for Atg2a is active, suggesting that it may be the source
of miR-192 and miR-194 in the pancreas.
Cis-regulatory elements of differentially expressed
microRNA genes
Next we employed positional weight matrices (PWMs)
to identify potential binding sites of tissue-enriched
Figure 1. Differential expression of microRNAs in three endoderm-derived tissues. microRNAs were identiﬁed as differentially expressed in (A) liver
versus small intestinal epithelium, (B) liver versus pancreas and (C) small intestine versus pancreas using an FDR of 10% and a minimum fold
change of 1.5 . Several abundant microRNAs such as mmu-miR-192 are expressed at similar levels in both tissues (dots near the orange line). Each
tissue has one highly-expressed, highly-differential microRNA as well as  30 other microRNAs that exhibit signiﬁcant differential expression, which
are highlighted in green (down) and red (up).
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the best match to each PWM in the conserved regions
surrounding the TSSs (for simplicity referred to as ‘pro-
moters’ below) with their occurrence in randomly se-
lected promoters from protein-coding genes. We used
the sets of promoters that were associated with liver-,
small intestine-, or pancreas-enriched microRNAs.
Because we were interested in identifying motifs that
may cover only a subset of microRNA promoters, we
developed a novel enrichment statistic that empha-
sizes the enrichment of high-scoring motif matches in
a group of promoters, but does not require
strong motifs in all or even most of the tissue-speciﬁc
promoters (see ‘Materials and Methods’ section for
details).
In the set of liver-enriched microRNA genes, predicted
sites for the factors MYB (M00183, pv=3.1e–5), and
SREBP (M01168, pv=4.8e–3) were enriched within
1000bp of H3K4me3 regions. Considering just the
miRNA-only H3K4me3 regions, we found CREB
(M00916 pv=1.2e–4), AHR/ARNT (M00778
pv=1.8e–4 or M00237 pv=2.6e–3) and E2F (M00938
pv=6.8e–3) to be enriched within 3000–8000bp. All of
these factors are known to be relevant to the function of
the liver. Because of the major role played by the nuclear
receptor HNF4a in gene regulation in hepatocytes, we
assessed the potential for regulation of liver microRNAs
by HNF4a using a recently developed support vector
machine-based prediction method (14), and found the
HNF4a motif signiﬁcantly enriched (corrected
P-value=0.0052) among the liver-expressed microRNA
promoters. In fact, eight microRNA genes expressed pref-
erentially in the liver contain predicted HNF4a-binding
sites above the recommended threshold. We note that
HNF4a is a hepatocyte-speciﬁc transcription factor
which is not expressed in all cell types in the liver; there-
fore, there may be a set of liver-speciﬁc miRNAs that are
not expressed hepatocytes, for which HNF4a is irrelevant.
Next, we sought experimental evidence of binding of
tissue-speciﬁc transcriptional regulators near microRNA
TSSs. Foxa2 is an important transcriptional regulator of
liver development and function (11,24–29) so we checked
previously published experimental data for Foxa2 binding
(13) and found that indeed seven of the putative
liver-enriched microRNAs TSSs (associated with 10
microRNAs) were within 2KB of experimentally deﬁned
Foxa2 sites (Table 5). A further eight miRNA had a
Foxa2 site within 15kb of the TSS. Four of the miRNA
TSS were not associated with a protein-coding gene and
thus represent evidence of miRNA-speciﬁc regulation by
Table 1. Top 20 microRNAs enriched in liver versus jejunum and/or
Pancreas
miRNA Liver
[RPM]
Ratio
[log2]
Jejunum
[RPM]
Ratio
[log2]
Pancreas
[RPM]
mmu-miR-122 447350.96 13.69 33.75 15.99 6.86
mmu-miR-122-3p 188.71 9.53 0.25 9.96 0.19
mmu-miR-1948 138.99 6.96 1.12 8.86 0.3
mmu-miR-485* 102.56 8.57 0.27 6.22 1.37
mmu-miR-455 199.55 6.16 2.78 6.49 2.23
mmu-miR-21 27344.49 – – 5.53 591.84
mmu-miR-340-5p 332.16 2.26 69.11 5.53 7.21
mmu-miR-193 116.31 5.4 2.76 – –
mmu-miR-101b 6708.91 2.79 968.95 5.29 171.02
mmu-miR-1937a 86.26 5.26 2.25 5 2.69
mmu-miR-30a* 881.83 5.03 26.96 1.64 282.37
mmu-miR-30c-2* 244.84 4.95 7.94 – –
mmu-miR-107 7795.86 2.92 1032.13 4.82 276.37
mmu-miR-22* 269.87 4.62 10.96 4.45 12.38
mmu-miR-31 578.92 – – 4.58 24.21
mmu-miR-99a 394.09 4.48 17.63 – –
mmu-miR-221 1992.34 4.48 89.2 – –
mmu-miR-29b-2 294.92 – – 4.46 13.43
mmu-miR-192 136451.85 – – 4.31 6889.72
mmu-miR-98 770.18 2.51 135.44 4 48.17
mmu-miR-127 352.69 3.96 22.7 – –
mmu-miR-486 185.32 3.95 11.98 1.66 58.51
mmu-miR-194-2 719.8 – – 3.93 47.28
mmu-miR-451 730.88 3.89 49.29 – –
mmu-miR-125b-1-5p 320.5 3.8 23.05 – –
mmu-miR-541 101.72 3.8 7.32 1.63 32.79
mmu-miR-142-5p 228.22 – – 3.63 18.38
mmu-miR-125a-5p 627.32 3.63 50.61 – –
mmu-miR-130a 429.6 3.45 39.31 3.61 35.08
mmu-miR-126-5p 120.17 3.37 11.66 3.54 10.33
All expression levels are expressed as reads per million. Selection was
based on a fold change of at least 1.5 and a false discovery rate of
10%.
Table 2. microRNAs enriched in Small Intestine versus Liver and/or
Pancreas
miRNA Jejunum
[RPM]
Ratio
[log2]
Liver
[RPM]
Ratio
[log2]
Pancreas
[RPM]
mmu-miR-215 447350.96 14.71 16.73 14.21 23.66
mmu-miR-215-3p 2221.8 13.49 0.19 13.4 0.21
mmu-miR-194-1 3448.07 9.99 3.38 11.36 1.31
mmu-miR-200c 3495.91 9.33 5.41 – –
mmu-miR-375 408.84 8.78 0.93 – –
mmu-miR-145 4903.86 8.49 13.6 – –
mmu-miR-194-1-3p 63.24 8.36 0.19 8.39 0.19
mmu-miR-141 68 7.86 0.29 2.61 11.12
mmu-miR-363-5p 68.34 5.88 1.16 7.31 0.43
mmu-miR-429 693.71 7.3 4.4 2.55 118.23
mmu-miR-1-1 1429.3 6.34 17.67 7.13 10.18
mmu-miR-200a 4802.45 6.53 51.99 2.03 1179.74
mmu-miR-200b 3905.74 6.43 45.17 – –
mmu-miR-194-2 3769.81 2.39 719.8 6.32 47.28
mmu-miR-33 136.43 1.53 47.12 6.23 1.81
mmu-miR-200b* 401.44 5.93 6.6 1.48 143.63
mmu-miR-31 1343.17 1.21 578.92 5.79 24.21
mmu-miR-21 31885.58 – – 5.75 591.84
mmu-miR-142-5p 986.36 2.11 228.22 5.75 18.38
mmu-miR-130b 82.83 5.68 1.61 – –
mmu-miR-1-2 880.44 5.64 17.67 5.61 18.04
mmu-miR-142-3p 108.57 4.96 3.49 4 6.78
mmu-miR-20a 94.27 3.56 8.02 4.6 3.89
mmu-miR-872 58 – – 4.58 2.42
mmu-miR-1274a 61.77 4.31 3.12 – –
mmu-miR-182 63.73 4.07 3.8 – –
mmu-miR-192 102132.57 – – 3.89 6889.72
mmu-miR-143 1357.07 3.79 98.12 – –
mmu-miR-29b-2 172.11 – – 3.68 13.43
mmu-miR-203 1660.92 2.66 262.14 3.63 134.5
All expression levels are in RPM. Selection was based on a fold change
of at least 1.5 and a false discovery rate of 10%.
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where we have identiﬁed a novel liver-speciﬁc
microRNA TSS that is occupied by Foxa2 within a few
hundred base pairs of the TSS.
CONCLUSIONS
Here we have taken advantage of the substantial dynamic
range of ultra-high throughput sequencing to detect and
quantify microRNAs in three endoderm-derived tissues.
Many of the microRNAs identiﬁed here had been
missed in previous studies (21). However, despite the
fact that we obtained >90 million sequence reads for
small RNAs, no new microRNAs were discovered,
strongly suggesting that mirBase covers all or nearly all
existing microRNA genes.
As one might expect for developmentally related tissues
such as liver, jejunum and pancreas, most of the
microRNA genes are expressed at roughly similar levels
in the three tissues. However, we also discovered
tissue-speciﬁc expression between pairs of tissues, in
some cases over several orders of magnitude. We utilized
experimental mapping of transcriptional start sites in
order to localize the promoters that direct this
tissue-speciﬁc gene activation. Importantly, we found
multiple cases where different transcriptional start sites
are used by microRNA genes in endoderm-derived
tissues as opposed to embryonic stem cells. These
ﬁndings suggest that understanding microRNA gene pro-
moters requires their experimental validation in each
tissue of interest. We did not measure repressive chroma-
tin marks, e.g. H3K27me3, in this work, so potentially
active H3K4me3-marked TSS need to be evaluated for
absence of repressive marks to further validate their
activity.
Finally, we analyzed the cis-regulatory elements that
contribute to the regulation of microRNA gene expres-
sion in liver, jejunum, and pancreas. We ﬁnd that the
same major transcription factors that regulate the
tissue-speciﬁc expression of protein-coding genes also
contribute to the regulation of microRNA genes,
suggesting that both classes of genes utilize the same
fundamental regulatory mechanisms. These results
extend earlier ﬁndings by others. For example,
Table 3. microRNAs enriched in pancreas versus liver and/or small intestine
miRNA Pancreas
[RPM]
Ratio
[log2]
Liver
[RPM]
Ratio
[log2]
Jejunum
[RPM]
mmu-miR-375 115969.49 16.93 0.93 8.15 408.84
mmu-miR-217 3177.41 10.54 2.13 12.77 0.46
mmu-miR-216b 257.11 8.88 0.55 9.26 0.42
mmu-miR-200c 2528.08 8.87 5.41 – –
mmu-miR-672 226.77 8.23 0.75 4.29 11.62
mmu-miR-138-1 89.86 8.22 0.3 4.12 5.16
mmu-miR-676 779.03 3.98 49.21 8 3.05
mmu-miR-184 173.65 7.44 1 5.4 4.1
mmu-miR-148a 24381.18 3.82 1721.49 6.86 209.89
mmu-miR-148a* 63.48 4.77 2.33 6.76 0.58
mmu-miR-99a 1814.3 2.2 394.09 6.69 17.63
mmu-miR-145 1353.92 6.64 13.6 – –
mmu-miR-200b 3572.31 6.31 45.17 – –
mmu-miR-183 72.59 6.21 0.98 – –
mmu-miR-10b 50.92 6.2 0.69 2.46 9.27
mmu-miR-7b 16.55 6.02 0.25
mmu-miR-155 20.46 5.88 0.35 2.95 2.65
mmu-miR-2143-3 494.87 5.78 9 4.17 27.48
mmu-miR-130b 79.92 5.63 1.61 – –
mmu-miR-224 13.32 5.3 0.34 – –
mmu-miR-141 11.12 5.25 0.29 – –
mmu-miR-802 78.2 5.25 2.06 1.3 31.67
mmu-miR-676* 39.2 2.06 9.4 5.17 1.09
mmu-miR-152 18175.19 3.15 2053.99 5.04 552.97
mmu-miR-2133-2-3p 86.25 4.96 2.78 4.97 2.75
mmu-miR-802-3p 112.04 4.88 3.81 1.55 38.37
mmu-miR-1195-3p 254.2 4.77 9.35 3.86 17.51
mmu-miR-429 118.23 4.75 4.4 – –
mmu-miR-34a 25.21 4.74 0.95 4.22 1.35
mmu-miR-1274a 78.33 4.65 3.12 – –
All expression levels are in RPM. Selection was based on a fold change of at least 1.5 and a false discovery rate of 10%.
Table 4. Overlap between putative miRNA TSS and other regulatory
features
Organ TSS
Regions
CpG Island,
%
ESC Promoters,
%
Foxa2 Sites,
%
Liver 74 77.0 62.2 10.8
Jejunum 75 73.3 66.7 8.0
Pancreas 76 77.6 64.5 9.2
All 106 74.5 55.7 7.5
Nucleic AcidsResearch, 2011, Vol.39,No. 2 459Figure 2. Transcriptional start sites of microRNAs enriched in the liver. (A) Shows mmu-miR-122 that is highly expressed in liver and expressed
about 1000–2000  lower in jejunal epithelium and pancreas. Each section (liver, jejunum, and pancreas) shows the proﬁle of H3K4me3, regions of
signiﬁcant levels of H3K4me3, the link from the miRNA to the nearest H3K4me3 peak, and the log2 normalized expression level of miRNAs. Note
the presence of H3K4me3-modiﬁed histones at the transcriptional start site in the liver (olive). No H3K4me3 is present in jejunum (purple) or
pancreas (yellow). Additionally, this TSS was not identiﬁed in mouse embryonic stem cells [TSS from (23) in magenta]. This locus also includes an
example of Foxa2 binding. In (B), mmu-miR-101b is located within the protein-coding Rcl1 gene, which is not highly expressed in liver, yet the
microRNA TSS shows clear evidence of liver-speciﬁc H3K4me3. mmu-miR-101b is expressed at lower levels in jejunum and pancreas and may the
use Rcl1 promoter.
460 Nucleic Acids Research, 2011,Vol. 39,No. 2Figure 3. Transcriptional start sites of microRNAs enriched in the small intestinal epithelium or pancreas. (A) mmu-miR-215 and mmu-miR-194-1
are speciﬁc to jejunum and have a strong proximal jejunum-speciﬁc H3K4me3 region which is internal to the Iars2 gene. (B) mmu-miR-375, situated
just downstream of Ccdc108 gene, has an adjacent region of H3K4me3 [also identiﬁed in ref. (23)] that is absent in liver and jejunum. mmu-miR-375
is expressed in jejunum, but the promoter identiﬁed is at the Ihh gene about 50-kb upstream.
Nucleic AcidsResearch, 2011, Vol.39,No. 2 461SREBP-1c has been shown to indirectly regulate
miRNAs in skeletal muscle in response to insulin signal-
ing (30), so it is exciting to ﬁnd evidence for a direct link
in liver between SREBP-1c and microRNA regulation, as
this is a tissue which also responds to insulin. Similarly,
c-Myb has been shown to be both a target and a
regulator of miRNA-15a in K562 myeloid leukemia
cells (31).
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Supplementary Data are available at NAR Online.
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Figure 4. Transcriptional start sites for miR-192 and miR-194 which are expressed in all three tissues, but at decreased levels in pancreas where the
H3K4me3 region at chr19:6263000 is nearly absent. The ES-cell promoter from (23) does not appear to be active in any of these tissues, but a CpG+
promoter for the Atg2 gene is active and may be the source of these miRNAs in the pancreas.
Table 5. Location of Foxa2 sites within 10kb of miRNA/TSS
Foxa2 Location TSS/miRNA Location Distance [bp] miRNA
chr11:86403625–86403809 chr11:86400262–86403879 162 mmu-mir-21
chr6:31152438–31152697 chr6:30992823–31151892 675 mmu-mir-29a
chr1:196718801–196719044 chr1:196717762–196737844 1160 mmu-mir-29b-2
chr1:196718801–196719044 chr1:196717762–196738358 1160 mmu-mir-29c
chr5:138400937–138401132 chr5:138395109–138402675 1641 mmu-mir-25
chr5:138400937–138401132 chr5:138395311–138402675 1641 mmu-mir-93
chr4:100854070–100854278 chr4:100844877–100855891 1717 mmu-mir-101a
chr19:29194307–29194636 chr19:29192749–29201372 1722 mmu-mir-101b
chr5:138400704–138400930 chr5:138395109–138402675 1858 mmu-mir-25
chr5:138400704–138400930 chr5:138395311–138402675 1858 mmu-mir-93
chr4:100853701–100853887 chr4:100844877–100855891 2097 mmu-mir-101a
chr16:18255150–18255448 chr16:18240964–18257550 2251 mmu-mir-185
chr5:119931308–119931521 chr5:119786217–119936556 5142 mmu-mir-1959
chr13:48564064–48564222 chr13:48547949–48558966  5177 mmu-let-7d
chr13:48564064–48564222 chr13:48549766–48558966  5177 mmu-let-7f-1
chr13:48564064–48564222 chr13:48550116–48558966  5177 mmu-let-7a-1
chr11:79470698–79470956 chr11:79476766–79542706  5939 mmu-mir-365-2
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